Ann: Trading Halt, page-30

Hi IHS

Another aspect which I think makes PTX stand out as an investment compared with other cancer biotechs is its business model.

Steve Yatomi-Clarke likes to refer to this as a “shovels to the goldrush” model.

Other than its own internal cancer programs (currently 2 clinical-stage targeted therapies and 3 preclinical-stage CAR-T therapies), PTX has three separate platforms available for outlicensing.

• The OMNICAR platform, which other companies can license to pursue their own targets.
• CellPryme- M, which can be easily incorporated into the cell-manufacturing process of any other CAR-T company. It optimises the cells to be used in treatment so they are more persistent. It can be also be used with existing suboptimal CAR-T therapies.
• CellPryme-A, an adjunct therapy which is administered alongside a patient’s CAR-T therapy. It improves tumour killing and host survival of the CAR-T therapy when used in solid cancers and these benefits can be further maximised if CellPryme-M is also used.

The three platforms can be used separately, or combined.

PTX owns the IP for both CellPryme-M and CellPryme-A.